JBPOS0422

JBPOS0422 is a preclinical-stage small molecule developed by Bio-Pharm Solutions for the treatment of epilepsy and pain management. The compound was selected for inclusion in the NIH NINDS (National Institute of Neurological Disorders and Stroke) Red Book, a designation for compounds that have demonstrated significant activity within the Epilepsy Therapy Screening Program (ETSP). Bio-Pharm Solutions focuses on developing novel treatments for central nervous system (CNS) disorders, and JBPOS0422 represents a follow-up asset to their more advanced clinical programs. While its specific mechanism of action has not been publicly disclosed, it is part of a chemical series designed to address treatment-resistant neurological conditions.